Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
| Autor: | Nese Saltoglu, Ziya Kuruüzüm, Nesrin Türker, Petek Konya, Alper Şener, Uluhan Yıldız, Gunay Tuncer Ertem, Kaya Suer, Bilgehan Aygen, Hüseyin Bilgin, Dilara Inan, Onur Ural, Bahar Ormen, Nazlim Aktug Demir, Sumeyra Simsek, Orhan Yildiz, Reşit Mistik, Hüseyin Tarakçı, Nurhan Doğan, Pinar Korkmaz, Rıza Aytaç Çetinkaya, Emine Türkoğlu, Deniz Kamalak Güzel, Gülden Ersöz, Neşe Demirtürk, Ismail Necati Hakyemez, Yunus Gürbüz, Faruk Karakeçili, Necla Tulek, Sami Kinikli, Atahan Cagatay, Nazan Tuna, Ayse Batirel, Ali Asan, İlhami Çelik, Mustafa Kemal Çelen, Sener Barut, Selcan Arslan Ozel, Funda Şimşek, Sıla Akhan, Sinan Ozturk |
|---|---|
| Přispěvatelé: | Demirtürk, Neşe, Türkoğlu, Emine, Doğan, Nurhan, Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı, Çelen, Mustafa Kemal |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Ledipasvir
medicine.medical_specialty Sofosbuvir Side effect Turkey Genotype Hepacivirus Chronic hepatitis C Antiviral Agents chemistry.chemical_compound Internal medicine Ribavirin Medicine Humans Infectious disease (athletes) Adverse effect Fluorenes business.industry Gastroenterology Hepatitis C Chronic Hepatitis C Real-world data Discontinuation Sustained virological response Treatment Outcome chemistry Original Article Benzimidazoles Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Turk J Gastroenterol |
| Popis: | WOS:000648816400007 PMID: 33960939 Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV +/- RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. Results: A total of 552 patients were included in the study. The mean age of the patients was 51.28 +/- 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV +/- RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. Conclusion: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV +/- RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|